SG11202000197PA - Immunogenic compositions comprising cea muc1 and tert - Google Patents
Immunogenic compositions comprising cea muc1 and tertInfo
- Publication number
- SG11202000197PA SG11202000197PA SG11202000197PA SG11202000197PA SG11202000197PA SG 11202000197P A SG11202000197P A SG 11202000197PA SG 11202000197P A SG11202000197P A SG 11202000197PA SG 11202000197P A SG11202000197P A SG 11202000197PA SG 11202000197P A SG11202000197P A SG 11202000197PA
- Authority
- SG
- Singapore
- Prior art keywords
- muc1
- cea
- tert
- immunogenic compositions
- immunogenic
- Prior art date
Links
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531227P | 2017-07-11 | 2017-07-11 | |
| US201862682044P | 2018-06-07 | 2018-06-07 | |
| PCT/IB2018/054926 WO2019012371A1 (en) | 2017-07-11 | 2018-07-03 | Immunogenic compositions comprising cea muc1 and tert |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000197PA true SG11202000197PA (en) | 2020-02-27 |
Family
ID=63720720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000197PA SG11202000197PA (en) | 2017-07-11 | 2018-07-03 | Immunogenic compositions comprising cea muc1 and tert |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190016775A1 (en) |
| EP (1) | EP3651792A1 (en) |
| JP (2) | JP7028953B2 (en) |
| KR (1) | KR20200027551A (en) |
| CN (1) | CN111065408A (en) |
| AU (1) | AU2018300295A1 (en) |
| BR (1) | BR112020000413A2 (en) |
| CA (1) | CA3069363A1 (en) |
| CO (1) | CO2020000231A2 (en) |
| IL (1) | IL271917A (en) |
| PE (1) | PE20200613A1 (en) |
| PH (1) | PH12020500087A1 (en) |
| RU (1) | RU2020100072A (en) |
| SG (1) | SG11202000197PA (en) |
| TW (1) | TW201920674A (en) |
| WO (1) | WO2019012371A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102020201219A1 (en) | 2020-01-31 | 2021-08-05 | United Initiators Gmbh | Transport and storage containers for peroxides |
| CN112552380B (en) * | 2020-12-10 | 2021-12-24 | 武汉博沃生物科技有限公司 | Immunogen of SARS-CoV-2 virus and its application |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| CA1341482C (en) | 1984-10-31 | 2005-05-10 | Paul A. Luciw | Process for preparing fragments of aids-associated retroviruses |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5817491A (en) | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US6962790B1 (en) | 1998-09-23 | 2005-11-08 | University Of Massachusetts Medical Center | Predictive assay for immune response |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| TWI228718B (en) | 2001-11-05 | 2005-03-01 | Tdk Corp | Manufacturing method and device of mold plate for information medium |
| DE10162480A1 (en) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
| LT2163260T (en) | 2004-01-23 | 2017-06-26 | Msd Italia S.R.L. | Chimpanzee adenovirus vaccine carriers |
| NZ576134A (en) * | 2006-10-12 | 2011-09-30 | Angeletti P Ist Richerche Bio | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
| KR101783004B1 (en) | 2008-07-08 | 2017-09-28 | 인사이트 홀딩스 코포레이션 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| SG172935A1 (en) | 2009-02-02 | 2011-08-29 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| US9128725B2 (en) | 2012-05-04 | 2015-09-08 | Apple Inc. | Load-store dependency predictor content management |
| WO2014079886A1 (en) * | 2012-11-20 | 2014-05-30 | Sanofi | Anti-ceacam5 antibodies and uses thereof |
| JP2014161283A (en) * | 2013-02-26 | 2014-09-08 | Shizuoka Prefecture | Splicing variants of ceacam5 gene |
| SG11201510748PA (en) * | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating lung cancer |
| WO2015063674A1 (en) | 2013-10-28 | 2015-05-07 | Piramal Enterprises Limited | Herbal composition, process for its preparation and use thereof |
| BR112016008806A2 (en) | 2013-11-01 | 2017-10-03 | Pfizer | VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS |
| MD20160118A2 (en) | 2014-05-15 | 2017-04-30 | Iteos Therapeutics | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors |
| TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
| EP3242940B1 (en) * | 2015-01-09 | 2023-03-29 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2018
- 2018-07-03 SG SG11202000197PA patent/SG11202000197PA/en unknown
- 2018-07-03 BR BR112020000413-8A patent/BR112020000413A2/en not_active Application Discontinuation
- 2018-07-03 WO PCT/IB2018/054926 patent/WO2019012371A1/en unknown
- 2018-07-03 RU RU2020100072A patent/RU2020100072A/en unknown
- 2018-07-03 CA CA3069363A patent/CA3069363A1/en not_active Abandoned
- 2018-07-03 JP JP2020500687A patent/JP7028953B2/en active Active
- 2018-07-03 KR KR1020207003864A patent/KR20200027551A/en not_active Application Discontinuation
- 2018-07-03 PE PE2020000050A patent/PE20200613A1/en unknown
- 2018-07-03 EP EP18780215.2A patent/EP3651792A1/en not_active Withdrawn
- 2018-07-03 CN CN201880057887.4A patent/CN111065408A/en active Pending
- 2018-07-03 AU AU2018300295A patent/AU2018300295A1/en not_active Abandoned
- 2018-07-06 TW TW107123509A patent/TW201920674A/en unknown
- 2018-07-09 US US16/029,878 patent/US20190016775A1/en not_active Abandoned
-
2020
- 2020-01-08 IL IL271917A patent/IL271917A/en unknown
- 2020-01-10 PH PH12020500087A patent/PH12020500087A1/en unknown
- 2020-01-10 CO CONC2020/0000231A patent/CO2020000231A2/en unknown
-
2021
- 2021-10-27 JP JP2021175480A patent/JP2022031653A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190016775A1 (en) | 2019-01-17 |
| BR112020000413A2 (en) | 2020-07-21 |
| JP7028953B2 (en) | 2022-03-02 |
| AU2018300295A1 (en) | 2020-01-23 |
| RU2020100072A3 (en) | 2021-08-11 |
| CA3069363A1 (en) | 2019-01-17 |
| KR20200027551A (en) | 2020-03-12 |
| PH12020500087A1 (en) | 2020-09-14 |
| RU2020100072A (en) | 2021-08-11 |
| JP2020526202A (en) | 2020-08-31 |
| TW201920674A (en) | 2019-06-01 |
| CO2020000231A2 (en) | 2020-01-17 |
| PE20200613A1 (en) | 2020-03-11 |
| WO2019012371A1 (en) | 2019-01-17 |
| JP2022031653A (en) | 2022-02-22 |
| CN111065408A (en) | 2020-04-24 |
| EP3651792A1 (en) | 2020-05-20 |
| IL271917A (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201905792B (en) | Hair-treatment compositions | |
| IL280134A (en) | Anti-cd112r compositions and methods | |
| EP3292168A4 (en) | High strength silicone elastomers and compositions therefor | |
| IL268970A (en) | Novel compositions and methods | |
| ZA201901032B (en) | Immunogenic/therapeutic glycan compositions and uses thereof | |
| EP3188749A4 (en) | Tolerogenic compositions and methods | |
| IL271275A (en) | Compositions comprising curons and uses thereof | |
| IL269590A (en) | Methods and compositions for reduction of immunogenicity | |
| GB201807325D0 (en) | Compositions and methods | |
| GB202201860D0 (en) | Novel methods and compositions | |
| EP3688097A4 (en) | Silicone composition comprising filler | |
| EP3193919A4 (en) | Immunogenic/therapeutic glycoconjugate compositions and uses thereof | |
| EP3215163A4 (en) | Beta-glucan methods and compositions that affect the tumor microenvironment | |
| GB201711635D0 (en) | Immunogenic composition | |
| EP3645043A4 (en) | Methods and compositions for dectin-2 stimulation and cancer immunotherapy | |
| EP3388488A4 (en) | Addition-curable silicone rubber composition and silicone rubber | |
| EP3688069A4 (en) | Silicone compositions | |
| EP3518955A4 (en) | Tert immunogenic compositions and methods of treatment using the same | |
| ZA202004317B (en) | Immunostimulatory compositions | |
| GB201818084D0 (en) | Compositions and methods | |
| GB201711637D0 (en) | Immunogenic composition | |
| IL271917A (en) | Immunogenic compositions comprising cea muc1 and tert | |
| GB201817444D0 (en) | Methods and compositions | |
| EP3197488A4 (en) | Compositions comprising ch505 envelopes, and trimers | |
| ZA202004533B (en) | Skin-brightening compositions and methods |